Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2009

View Archived Issues

Freie Universitaet Berlin claims novel pepstatin A derivatives

CKD Pharmaceuticals describes discovery of PDE5 inhibitor CKD-533

Activity of nab-rapamycin against breast cancer xenografts enhanced by other agents

Synergistic growth inhibition seen with BEZ-235 and dual EGFR and HER-2/neu inhibitor

Novel Raf kinase inhibitors presented by Wyeth as oncolytics

Esteve discloses 5-HT6 receptor ligands for the treatment of eating disorders

Novel HDAC inhibitors being developed by EnVivo Pharmaceuticals and MethylGene

Pim kinase inhibitors claimed by Novartis for the treatment of cancer

Novel Raf kinase inhibitors described by Novartis for the treatment of cancer

Takeda discovers a novel series of AMPA glutamate receptor agonists

Phase I results suggest ARRY-380 is well tolerated, active in breast cancer patients

Novo Nordisk provides update on timeline for formal FDA feedback on liraglutide

Santarus submits IND for phase III rifamycin SV MMX trial

FDA accepts NDA filing for Valeant's retigabine

Pfizer discontinues phase III figitumumab trial in non-small cell lung cancer

FDA issues complete response letter for ceftobiprole

MedImmune voluntarily recalls specific lots of 2009 H1N1 nasal spray vaccine

FDA review of Vytorin deems cancer risk "unlikely"

FDA responds to Vion's SPA request regarding Onrigin

Biotec sells Immunocorp subsidiaries in order to focus on biopharmaceuticals

Meda expands collaboration for Axorid

Clinical study of NPC-1C begins for pancreatic and colorectal cancer

BGC-20-0134 moves into phase II investigation for relapsing remitting MS

LEO-29102 enters phase II study for atopic dermatitis

Merck identifies novel macrocyclic hepatitis C NS3/4A protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...